Rising global fungal infections represent a significant public health burden,which are among the most difficult diseases to manage in humans.Candida spp,a major aetiologic agent of fungal infections,can cause severe invasive and systemic diseases that can even be deadly.On March 22,2023,the FDA approved a novel echinocandin antifungal rezafungin to treat candidemia and invasive candidiasis.Clinical studies have shown that rezafungin has a good efficacy and safety for candidiasis infections.This review describes its pharmacological action,clinical evaluation,safety,usage and dosage.
NETL
NSTL
万方数据
